UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 20, 2015

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

BioCryst Pharmaceuticals, Inc.

File No. 0-23186 - CF#31797

BioCryst Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 7, 2014.

Based on representations by BioCryst Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through August 11, 2024
Exhibit 10.2	through August 27, 2024
Exhibit 10.3	through September 17, 2024
Exhibit 10.4	through October 29, 2024

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary